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Abstract
Even the highest quality evidence will have little impact unless it is incorporated into decision-making for health. It is
therefore critical to overcome the many barriers to using evidence in decision-making, including (1) missing the window
of opportunity, (2) knowledge gaps and uncertainty, (3) controversy, irrelevant and conflicting evidence, as well as
(4) vested interests and conflicts of interest. While this is certainly not a comprehensive list, it covers a number of main
themes discussed in the knowledge translation literature on this topic, and better understanding these barriers can help
readers of the evidence to be more savvy knowledge users and help researchers overcome challenges to getting their
evidence into practice. Thus, the first step in being able to use research evidence for improving population health is
ensuring that the evidence is available at the right time and in the right format and language so that knowledge users
can take the evidence into consideration alongside a multitude of other factors that also influence decision-making. The
sheer volume of scientific publications makes it difficult to find the evidence that can actually help inform decisions for
health. Policymakers, especially in low- and middle-income countries, require context-specific evidence to ensure local
relevance. Knowledge synthesis and dissemination of policy-relevant local evidence is important, but it is still not
enough. There are times when the interpretation of the evidence leads to various controversies and disagreements,
which act as barriers to the uptake of evidence. Research evidence can also be influenced and misused for various aims
and agendas. It is therefore important to ensure that any new evidence comes from reliable sources and is interpreted
in light of the overall body of scientific literature. It is not enough to simply produce evidence, nor even to synthesize
and package evidence into a more user-friendly format. Particularly at the policy level, political savvy is also needed to
ensure that vested interests do not undermine decisions that can impact the health of individuals and populations.
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Background
Billions of dollars are spent each year on producing re-
search, but to what extent does all this research actually
serve to improve health outcomes? Notwithstanding the
value of creating knowledge for its own sake, it is diffi-
cult to justify spending limited resources on countless
research studies, especially where there is potential for
causing harm to research subjects (whether human or
animal), if this does not contribute to a deeper under-
standing of the world we live in and how to make it a
better place [1]. Even the highest quality evidence will
have no impact unless it is incorporated into decision-
making for health. Indeed, in recent years, there has
been a push towards closing the ‘know-do’ gap – i.e. the
gap between what we know works based on research
evidence and what we actually do in practice [2]. There
has also been an attempt to increase the likelihood of
evidence being used to change policy and practice
through co-production of knowledge between re-
searchers and policymakers [3], as well as increasing the
impact of research on improving health outcomes [4,5].
However, if our goal is to make more evidence-informed
decisions that improve health, it is critical to be aware of
the many barriers to using evidence in decision-making
and to overcome these so that we can facilitate translat-
ing research evidence into improved health outcomes.
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The purpose of this article is therefore to highlight and
better understand some of these barriers.
Review
There exists a large and growing literature on the bar-
riers to using evidence in decision-making for health.
Some of the key themes that are often discussed include
(1) missing the window of opportunity – often due to
the relatively long time-frame required to generate new
evidence and synthesize existing evidence and the rela-
tively short time-frame available for making decisions,
(2) knowledge gaps and uncertainty – especially the pau-
city of contextually-relevant evidence from local studies,
(3) controversy, irrelevant and conflicting evidence –
which act as smokescreens clouding the picture and
making it difficult to decide how best to proceed, as well
as (4) vested interests and conflicts of interest – which
deliberately manipulate the evidence base to the detri-
ment of the public’s health and wellbeing. These barriers
often stem from the complexity inherent to producing
knowledge, the disconnect between the worlds of
researchers and policymakers, intentional subverting of
the evidence for political or economic gain, or a combin-
ation of the above.
Missing the window of opportunity
The first step in being able to use research evidence is
ensuring that it is available at the right time and in the
right format [6], so that knowledge users can take the
evidence into consideration alongside a multitude of
other factors that also influence decision-making.
The window of opportunity for incorporating evidence
into decision-making can be very narrow, so unless the
‘work’ of having synthesized and packaged the evidence
into a usable format has already been done beforehand,
decisions are likely to be made without the aid of the
large scientific literature that may be available. For in-
stance, in the clinical setting, couples opting for prenatal
screening for Down syndrome must make very difficult,
morally-charged and potentially life-changing decisions
in just a few weeks, and frontline health workers are
making important treatment decisions on a daily basis
within a 10–20 minute time window during each patient
encounter. This explains why busy clinicians often turn
to ‘pre-digested’ evidence-based resources such as Up-
to-Date, JAMA Evidence and MD Consult, since these
are quick and easy to use, as well as being clinically rele-
vant, even if they come at a price. However, patients
rarely have access to such tools, or even to information
leaflets intended for patients which are not always dis-
tributed in practice, and therefore they must rely on
what they can recall from the medical visit or else risk
the information minefield which is the Internet. While
‘Googling’ for answers is certainly an option, there is a
great deal of misleading information on the Internet. At
the very least, it is important to use reputable websites
and, ideally, sites that adhere to the HONcode princi-
ples, which is a code of ethics for quality health and
medical information on the Internet [7].
In the policy world, the window of opportunity for
decision-making can also be very constrained. Whether
a controversy erupts in the media or an outbreak occurs,
decisions must often be made under pressure. A good
example of this is the policy response needed to deal
with the H5N1 bird flu outbreak in Hong Kong in 1997.
Margaret Chan, who was the Hong Kong Director of
Health at the time, had to make a policy decision within
48 hours. She decided, based on her professional experi-
ence and convictions, to cull 1.5 million chickens in
order to control the epidemic. While there are occasions
when governments have the luxury of commissioning re-
search from Health Technology Assessment agencies to
aid decision-making, there are also occasions when the
evidence is needed before the 5 pm press conference
and there is simply no time to embark upon a systematic
synthesis of the literature, even if one could call upon
the experts to do so.
Thus, it is advisable to foresee common and/or im-
portant decisions that must be made – whether in a
clinical setting or in a political context – and collect the
best available evidence in advance to lay out the options
and guide decision-makers through the pros and cons of
these various options. Of course, decision-making is not
straightforward, but rather a dynamic and non-linear
process [8], and evidence is only one type of input that
goes into this process (which also integrates many other
considerations such as valuations, preferences, feasibility,
cost, etc.). Nonetheless, evidence is more likely to be
used when it is available during the window of oppor-
tunity, if it points to options which are actionable and if
the existing resources and infrastructure can be used to
make it happen, rather than requiring an influx of new
resources [4]. For instance, one of the reasons for the
success of the Thai universal health coverage policy, in
addition to the solid evidence behind it, was that the
proponents underlined that it could be done within the
existing budget.
Knowledge gaps and uncertainty
Another major barrier to using evidence for informing
policy and practice is the lack of available evidence in
specific areas or in specific contexts. This can be ex-
tremely problematic. Particularly as we move away from
strictly clinical questions, such as the best pharmaceut-
ical treatment for hypertension or the best diagnostic
test for colon cancer, and attempt to address broader
social questions, such as how to tackle gender-based
violence and how to create supportive environments for
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health, we enter a realm where it is often difficult to be
entirely evidence-based because the evidence has not
been produced to the same extent. Since research re-
quires funding, and a great deal of research is privately
funded in part or in whole, it is not surprising that there
is relatively little research on issues such as gender-
based violence, child maltreatment or health inequities
more broadly, since there is no pill or product that can
be used to manage these health-related problems. Simi-
larly, when dealing with specific under-served popula-
tions, such as immigrants or Indigenous groups, one
may also run into the same problem that there is often
relatively little research evidence on ‘what works’ to
guide action in these specific populations, not to men-
tion the glaring research gap with respect to low- and
middle-income countries [9]. Even when there is solid
evidence at an international level, policymakers, espe-
cially in resource-constrained settings, often lack the
local evidence relevant to their particular context which
would be important in helping them make more in-
formed decisions for improving the health of their local
populations given the particular circumstances and chal-
lenges that they face.
A lack of evidence does not mean that the interven-
tions or strategies in question are not effective. It simply
means that they have not been sufficiently investigated.
The bottom line is that, in the absence of evidence, one
is left with a great deal of uncertainty under which deci-
sions must nonetheless be made. Therefore, at the very
least, it is necessary to gather together the best possible
evidence and to at least make explicit the knowledge
gaps. Indeed, there is no such thing as zero uncertainty
and therefore it is simply a matter of degree. Often pleas
for more research, while helpful, will generally not
provide the additional evidence required within the
timeline necessary to make decisions. Nonetheless, in
the meantime, decision-makers must resort to examin-
ing best practices or examples of what has worked in
different contexts to make the best possible decisions in
situations where there is a lack of guidance from the
existing body of research evidence.
Controversy, irrelevant and conflicting evidence
It is a strange paradox that, although we suffer from im-
portant knowledge gaps regarding how to improve popu-
lation health, the scientific literature is filled with a
plethora of ‘irrelevant evidence’ that is ‘nice to know’ but
not really what we ‘need to know’ to improve health. Re-
search topics chosen by researchers tend to be of aca-
demic interest, and only loosely driven by the information
needs of patients or decision-makers, if at all. It is there-
fore not surprising that the evidence produced then tends
to have little relevance or practical value for patient
choices or policymaking. According to the Agency for
Healthcare Research and Quality [10], before imple-
menting a new intervention, policymakers want to know
(1) can it work? (2) will it work here? and (3) is it worth
it? Yet, one must spend time going through a great deal of
irrelevant evidence to find patient-informed, policy-friendly
data that helps to answer these questions. As the number
of research publications continues to grow exponentially
(Fig. 1), it is becoming virtually impossible to keep abreast
of the scientific literature in any given field [11].
Beyond the lack of relevant evidence and the ‘noise’
created by irrelevant evidence, another challenge for
decision-making is disagreement about what the evidence
says. While generally evidence-based recommendations
are quite similar across jurisdictions and contexts [12],
there are occasions when different groups make re-
commendations based on the same international body of
evidence which are clearly at odds with the recom-















Fig. 1 The exponential increase in research evidence over the last century. Data based on articles indexed PubMed (http://www.ncbi.nlm.nih.gov/
pubmed/)
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confusion and contentious debate, which undermines
confidence in the scientific process, and is a major barrier
to the uptake and use of evidence.
The mammography controversy is a case in point [13].
When the Nordic Cochrane Centre published a system-
atic review in 2001 stating that “currently available reli-
able evidence does not show a survival benefit of mass
screening for breast cancer” it caused a great outcry [14].
There were many articles written condemning anyone
who dared to question the clinical utility of breast
screening as being part of an “active anti-screening cam-
paign… based on erroneous interpretation of data from
cancer registries and peer-reviewed articles” [15]. Indeed,
unlike the other reviews of breast cancer screening, the
Nordic review excluded certain studies for methodo-
logical reasons and included others, thereby arriving at a
different conclusion, which is certainly legitimate. How-
ever, the interpretation of the authors went a little too
far to counteract the then prevailing school of thought
on the benefits of screening. A few years later the Nordic
Cochrane Centre updated their analysis and revised their
conclusions to be more nuanced. The most recent up-
date of the review in 2011 states that “screening is likely
to reduce breast cancer mortality” – but, they qualify this
statement with an explanation [16]. The authors con-
clude that the mortality reduction attributable to screen-
ing is much lower than previously suggested by reviews
of the mammography literature (i.e. 15% versus 30%).
Further, overdiagnosis and overtreatment are much
more common than is generally acknowledged. Thus,
without rejecting breast screening altogether, the Nordic
Cochrane Centre provides the data for patients and pol-
icymakers to better weight the benefits and harms. If
people invited for screening only knew that, out of 2,000
women screened for 10 years, only one will avoid dying
from breast cancer, whereas 10 will receive unnecessary
treatment, and over 200 will experience a false alarm
requiring repeat testing and invasive diagnostic proce-
dures, they would be better equipped to judge for
themselves the merits of participating in the screening
program [17]. Indeed, if they choose to participate, they
may even find this information reassuring by knowing in
advance that false alarms are common and that only a
small proportion of women who are recalled for
additional testing actually have cancer.
Even though we all share the same international body
of research evidence, there is a great deal of subjectivity
in the analysis of that evidence [18]. There are times
when subtly different approaches to interpretation leads
to various controversies and disagreements, which act as
barriers to the uptake of evidence, whereas people
should be presented the evidence with all its nuances
and complexity, so that they can better choose for them-
selves. Since the body of evidence is not static, and the
knowledge base is constantly being revised and refined,
these controversies prove to be counter-productive and
claims that a single study can overturn decades of re-
search are misguided. Instead, the focus should be on
the quality and rigour of examining large bodies of
evidence produced over time and producing nuanced
information that is helpful for decision-makers [19].
However, of even greater concern is when the evidence
base is deliberately manipulated and misused with the
intention of promoting certain vested interests, as dis-
cussed in the following section.
Vested interests and conflicts of interest
The degree to which vested interests have infiltrated the
international body of evidence is not to be underesti-
mated. Often the way in which these interests play out
in the literature can be quite subtle. However, astute
readers of the literature should consider the underlying
motives behind research publications, and what the
authors stand to gain or lose. In areas such as tobacco
smoking, the introduction of new pharmaceuticals and
the manufacture and export of asbestos, the research
evidence can make or break an industry, with millions of
dollars as well as thousands of jobs at stake. Therefore,
there is a great deal to lose and tremendous incentive
for these mega-industries to prevent the diffusion of
studies which go against their commercial interests or
even actively infuse the larger body of evidence with
conflicting studies to raise some doubt as to whether
their product is indeed harmful – sufficient doubt to
allow the money-making enterprise to continue reaping
profits, even if only for a few more years. This sounds
very sinister and hard to believe, yet, there are regular
accounts of just this.
Indeed, a great deal has been written over the years
about how the tobacco industry has attempted in various
ways to call into question the link between smoking and
cancer by producing their own evidence – often flawed
or misinterpreted to their own ends [20]. The industry is
known to have co-opted a large number of “venal or
naive scientists” [21] and even commissioned consultants
to write articles that call into question the link between
second hand smoke (SHS) and sudden infant death syn-
drome (SIDS). According to internal memos made pub-
lic during legal action against the tobacco industry, there
is proof that tobacco company executives “successfully
encouraged one author to change his original conclusion
that SHS is an independent risk factor for SIDS to state
that the role of SHS is ‘less well established’…” [22]. The
author’s disclosure of industry funding did not reveal the
full extent of the company’s involvement in shaping the
content of the article. Yet another example of how
accepting industry funds can disrupt the integrity of the
scientific process.
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However, the tobacco industry is not the only culprit.
A great deal has also been written in the medical litera-
ture about the pharmaceutical industry introducing bias
which could have a favourable impact on medication
sales and ultimately increase profits for shareholders.
For instance, through “multiple publication of positive
trials and non-publication of negative trials, reinterpret-
ing data submitted to regulatory agencies, discordance
between results and conclusions, [and] conflict-of-interest
leading to more positive conclusions” [23].
Additionally, cash-strapped universities are increas-
ingly looking for alternative routes to fund-raising and
attempt to capitalize on the production of intellectual
property. Indeed, some universities have even developed
venture capital teams to support the roll-out and mar-
keting of scientific discoveries and technological innova-
tions developed on their campuses. Yet, a commitment
to open scientific inquiry and the pursuit of financial
gains are two goals that can be very difficult to reconcile,
often requiring a number of safeguards to be in place
[24]. Even beyond academia, governments are also impli-
cated. In the interest of keeping the economy running
and creating more jobs, governments are often eager
supporters of new industrial sectors. For instance, the
Canadian government is pouring money into genome re-
search [25], even though benefits to human health are
still unproven [26]. At times, these business ventures are
even shown to have serious negative consequences for
human health and well-being [27]. Nevertheless, any evi-
dence of such links must be quashed to avoid interfering
with economic gains and even with re-election. There-
fore, in certain situations, governments have been ac-
cused of obfuscating the truth [28]. For instance,
according to an editorial in the Canadian Medical
Association Journal [29], “Canada is the only Western
democracy to have consistently opposed international
efforts to regulate the global trade in asbestos. And the
government of Canada has done so with shameful
political manipulation of science”. However, Canada is
not alone when it comes to benefitting from ‘overlooking’
the evidence when it is inconvenient. Many countries, in-
cluding Mexico, Indonesia and China, in spite of having
ratified the Framework Convention on Tobacco Control,
continue to receive so much income from the sale of these
products through ‘sin taxes’ and other channels that they
have difficulty implementing measures intended to reduce
the use of tobacco products within their borders with the
aim of improving the health of their own people [30].
Even the ways in which health systems are organized
and run are not immune to the misappropriation of evi-
dence. Universal access to publicly-funded healthcare is
an important determinant of health [31] and “a privatized,
‘American-style’ health financing and provision system is
neither a feasible nor desirable model for developing
countries” [32]. Nonetheless, according to Whitehead et
al. [33], “In the past two decades, powerful international
trends in market-oriented health-sector reforms have been
sweeping around the world… advocated by agencies such
as the World Bank to promote privatisation”. Thus, the
authors call for an evidence-based approach to health sec-
tor reform, rather than promoting mass privatization of
healthcare services and charging poor people user fees,
which have been shown time and again to have negative
impacts on health [34,35]. Interestingly, under new leader-
ship, even the World Bank has done an abrupt turn in
support of universal health coverage, which “suggests that
an evidence-based approach to policy may finally be pre-
vailing over an ideologically driven approach” [36]. Thus,
there is hope that even the most powerful vested interests
can be overcome.
Conclusions
Readers of the scientific literature should be aware of
the ways in which the research evidence can be influ-
enced and misused for various aims and agendas. That
is not to say that we should throw out the whole
‘evidence-based’ enterprise, but simply that a healthy
dose of scepticism and critical thinking is advisable. It is
not enough to simply produce evidence, nor even to
synthesize and package evidence into a more user-
friendly format. New evidence needs to be critically ap-
praised and considered in light of the larger body of
existing scientific literature, both local and international.
Particularly at the policy level, political savvy is also
needed to ensure that vested interests do not undermine
decisions that can impact the health of individuals and
populations. Whether it is tobacco companies trying to
flood the literature with contradicting evidence or
pharmaceutical companies hiding research demonstrat-
ing that their products have no effect or lead to harm,
these conflicts of interest can lead us to make erroneous
conclusions and misinformed decisions. Ultimately, the
public pays the price, whether through poor health or
misspent money.
In response to these challenges, a growing number of
organisations, agencies, task forces and even global net-
works have been developed to synthesize, appraise and
disseminate research evidence with the goal of im-
proving health and reducing inequities. These include
the Cochrane and Campbell Collaborations [37], Health
Technology Assessment Agencies [38], the Canadian
Task Force on Preventive Health Care [39], and the US
Preventive Services Task Force [40], all of which focus
more on clinical-level guidance, as well as the Community
Guide, which focuses more on population-level health in-
terventions [41]. However, while finding, appraising and
synthesising the evidence and ‘putting it out there’ in a
clinical practice guideline, on a website or in a database is
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important, it is often not sufficient to ensure that the evi-
dence will be used to influence policy and practice.
Increasingly, it is being recognised that evidence needs to
be packaged in such a way so as to actively promote up-
take, since passive diffusion measures are much less likely
to have an impact [42].
Many different models are being developed to increase
the uptake and use of evidence in practice [43]. These
often involve some form of evidence summaries or
decision-support tools. For instance, the EVIPNet Portal
includes a repertory of EVIPNet Policy Briefs which
synthesise the research evidence and offer evidence-
informed and contextualised policy options in a user-
friendly format to support well-informed policy decisions
[44]. Public Health England’s Longer Lives/Healthier Lives
website is another example that provides statistical data
tools that allow people to see how their local area com-
pares to the rest of the country in terms of specific health
indicators and provides a route to existing evidence sum-
maries produced by the UK’s National Institute for Health
and Clinical Excellence [45]. Indeed, such policy briefs,
which are free from technical jargon and highlight key
messages in a brief executive summary, dramatically in-
crease the likelihood that policymakers will read, consider
and apply the evidence where appropriate. The EVIPNet
partners with multiple organisations to produce these
policy-relevant evidence syntheses, including the Alliance
for Health Policy and Systems Research, the Health
Evidence Network, and Supporting Policy relevant
Reviews and Trials. Similarly, the Cochrane Collaboration
produces Cochrane Summaries’ to make their systematic
reviews more readily accessible to a wider audience of
knowledge users [46].
While it is important to be aware of the barriers and
facilitators when using evidence in decision-making for
health, at the end of the day, a decision must be made
which takes into account the needs and concerns of the
individual patients and local populations involved. In the
next article in the series, a model for ensuring more par-
ticipatory, transparent and evidence-informed decisions
will be presented and discussed.
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